Upgrade to SI Premium - Free Trial

Pfizer (PFE) Reports Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin (trastuzumab) at ESMO 2017

September 11, 2017 5:56 AM
Pfizer Inc. (NYSE: PFE) today announced positive findings from REFLECTIONS B327-02 (n=707), a pivotal Phase 3 randomized, double-blind comparative safety ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Next Articles